Pacemakers made out of human stem cells may replace electronic models in future

sn pacemaker

The very first functional pacemaker cells created out of human stem cells have been developed by scientists from the McEwen Centre for Regenerative Medicine, at Toronto, Canada.

To date, electronic pacemakers are used to regulate heartbeat disorders of a human heart. The sinoatrial node (SAN) pacemaker cells are known to be the chief heartbeat controllers. A fault in its working can lead to irregular heartbeats and the treatment requires implantation of electronic pacemaker machines.

The effort made by scientists explains how human pluripotent stem cells can be developed into pacemaker cells in 21 days. These biological pacemaker cells can be used to replace the deteriorating SAN through cell transplantation.

The scientists formulated and tested the developmental pathway of creating pacemaker cells from stem cells by using different signaling molecules at different times, through the course of three weeks, till the goal was achieved.

“We are replicating nature’s way of making the pacemaker cell,” said the study’s senior author, Dr. Gordon Keller, Director of the McEwen Centre.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: Alternative Pacemaker Therapy: First Functional Pacemaker Cells Developed From Human Stem Cells

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Screenshot-2026-04-23-at-11.00.36-AM
Regulators' dilemma: Thalidomide, Metformin, and the cost of getting drug approvals wrong
Picture1-5
Science Disinformation Gap: The transatlantic battle over social media and censorship
ChatGPT-Image-May-13-2026-11_56_08-AM
After slashing global health aid by $19 Billion, Trump moves to tap $2.1 billion more—to cover shutdown costs
ChatGPT-Image-May-12-2026-08_39_41-PM
GLP podcast: Big Pharma, Big Ag, Big Food—health harming industries or life-saving innovators?
ChatGPT Image May 10, 2026, 08_16_59 PM 2
Overmedicalization? RFK Jr.’s antidepressant crackdown raises conflict questions over his fee stake in Wisner Baum, the tort firm built on suing drug makers
Screenshot-2026-05-12-at-9.58.31-PM
'He seems fine': Marty Makary out as FDA commissioner
Screenshot-2026-05-01-at-1.29.41-PM
Viewpoint: What happens when whole grains meet modern food manufacturing? Labels don’t tell the whole story.
ChatGPT-Image-Apr-13-2026-02_20_22-PM
Viewpoint: Misinformation infodemic? Why assessing evidence is so challenging 
Picture1-1
Cooling the planet with balloons: Could a geoengineering gamble slow global warming?
S
As vaccine rejectionism spreads, measles may be taking a more dangerous turn
Screenshot-2026-05-11-104424
Hantavirus outbreak research: Trump administration shut down study last year on rodent-to-human transmission
images
The never-ending GMO debate: Pros and cons
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.